The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...